Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
Key facts
- Where
- Tianjin, ChinaSee the site
Where in China
- Regenerative Medicine Center and Red Blood Cell Disorders CenterTianjin, ChinaContact: Weiwang Li, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT07461116
- Record updated
- 10 March 2026
- Original description
This prospective, single-center, observational cohort study aims to systematically observe and describe the clinical characteristics of adverse reactions in patients with aplastic anemia undergoing ATG (Anti-Thymocyte Globulin) /ALG (Anti-Lymphocyte Globulin) treatment, providing a data foundation for the development of relevant management strategies. This study plans to enroll 200 aplastic anemia patients undergoing ATG/ALG treatmentRead full original descriptionShow less
A Study on the Dynamics and Grading Criteria Construction of Adverse Reactions to ATG/ALG Therapy in Aplastic Anemia
This prospective, single-center, observational cohort study aims to systematically observe and describe the clinical characteristics of adverse reactions in patients with aplastic anemia undergoing ATG (Anti-Thymocyte Globulin) /ALG (Anti-Lymphocyte Globulin) treatment, providing a data foundation for the development of relevant management strategies. This study plans to enroll 200 aplastic anemia patients undergoing ATG/ALG treatment
Inclusion: Meet the diagnostic criteria for aplastic anemia (Camitta criteria); Receiving ATG/ALG immunosuppressive therapy for the first time.
Exclusion: Previously received hematopoietic stem cell transplantation; Aplastic anemia patients receiving ATG/ALG as part of transplant conditioning regimen.